GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

narsoplimab   Click here for help

GtoPdb Ligand ID: 14317

Synonyms: narsoplimab-wuug | OMS-721 | OMS721 | Yartemlea®
Approved drug
narsoplimab is an approved drug
Compound class: Antibody
Comment: Narsoplimab (OMS721) is a fully human IgG4 monoclonal antibody against mannan-binding lectin-associated serine protease 2 (MASP-2) [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Narsoplimab was first approved by the US FDA in December 2025, to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy. Development as a therapy for other microangiopathies such as IgA nephropathy and atypical hemolytic uremic syndrome has been discontinued.

COVID-19: narsoplimab was evaluated to treat complement-mediated activation of the immune system and microangiopathic endothelial cell damage in patients with severe COVID-19 [1,4].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03608033 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy Phase 3 Interventional Omeros Corporation This study was terminated as narsoplimab treatment did not provide efficacy with respect to the prespecified primary endpoint.
NCT04488081 I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients Phase 2 Interventional QuantumLeap Healthcare Collaborative
NCT05855083 Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA Phase 2 Interventional Omeros Corporation
NCT02222545 Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies Phase 2 Interventional Omeros Corporation 3